Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up

First Posted Date
2015-08-27
Last Posted Date
2017-03-14
Lead Sponsor
Fundación Marques de Valdecilla
Target Recruit Count
136
Registration Number
NCT02534363
Locations
🇪🇸

University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

First Posted Date
2015-08-18
Last Posted Date
2017-03-14
Lead Sponsor
Fundación Marques de Valdecilla
Target Recruit Count
203
Registration Number
NCT02526030
Locations
🇪🇸

University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date
2014-12-04
Last Posted Date
2018-10-11
Lead Sponsor
Technical University of Munich
Target Recruit Count
21
Registration Number
NCT02307396
Locations
🇩🇪

Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis

First Posted Date
2014-12-03
Last Posted Date
2017-03-14
Lead Sponsor
Fundación Marques de Valdecilla
Target Recruit Count
203
Registration Number
NCT02305823
Locations
🇪🇸

University Hospital Marques de Valdecilla, Santander, Cantabria, Spain

A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

First Posted Date
2014-07-17
Last Posted Date
2016-07-12
Lead Sponsor
Beijing HuiLongGuan Hospital
Target Recruit Count
550
Registration Number
NCT02192723
Locations
🇨🇳

Beijing HuiLongGuan Hospital, Beijing, China

Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

First Posted Date
2013-07-08
Last Posted Date
2015-03-17
Lead Sponsor
Guiyun Xu
Target Recruit Count
120
Registration Number
NCT01893229
Locations
🇨🇳

Guangzhou Psychiatric Hospital, Guangzhou, Guangdong, China

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

First Posted Date
2013-05-01
Last Posted Date
2016-02-05
Lead Sponsor
Northwell Health
Target Recruit Count
14
Registration Number
NCT01844700
Locations
🇺🇸

Zucker Hillside Hospital, Psychiatry Research, Glen Oaks, New York, United States

Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Ziprasidone
Drug: Aripiprazole
First Posted Date
2012-10-25
Last Posted Date
2012-11-27
Lead Sponsor
University of Malaya
Target Recruit Count
175
Registration Number
NCT01714011
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

First Posted Date
2011-12-23
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
42
Registration Number
NCT01498770
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy